Blue Cell Therapeutics

1 known investors

Blue Cell Therapeutics develops an off-the-shelf allogeneic stem cell therapy platform (Blue Cells) that promotes angiogenesis and nerve repair, with a lead candidate (BlueC-231) aimed at treating severe erectile dysfunction in men after radical prostatectomy. The company operates in the biotech and cell therapy space, targeting patients unresponsive to existing drug treatments.